Table 2.

Univariate and multivariate Cox proportional hazards regression analysis for disease specific survival in pT2 and pT3 cohorts

Univariate			Multivariate, model #1			Multivariate, model #2
Variable	n	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Gender
Male	214		ref			ref			ref
Female	67	1.31	0.87–1.96	0.20	1.51	0.98–2.32	0.06	1.42	0.93–2.18	0.11
Age
<60	77		ref			ref			ref
60–69	75	1.14	0.70–1.83	0.61	1.20	0.73–1.97	0.47	1.10	0.67–1.81	0.70
≥70	129	1.15	0.74–1.79	0.52	1.32	0.84–2.08	0.22	1.08	0.68–1.72	0.74
Grade
G1-2/low grade	18		ref			ref			ref
G3/high grade	253	2.48	0.92–6.74	0.074	2.02	0.73–5.65	0.18	2.33	0.84–6.45	0.10
p-Tcategory
pT2	120		ref			ref			ref
pT3	161	2.00	1.36–2.96	<0.001	1.85	1.24–2.77	0.003	1.95	1.29–2.94	0.001
Nodal status N0	143		ref			ref			ref
Npos	77	2.12	1.40–3.22	<0.001	1.98	1.28–3.06	0.002	2.16	1.37–3.39	0.001
Nx	61	1.52	0.94–2.44	0.085	0.95	0.55–1.63	0.85	1.56	0.92–2.66	0.10
Study Center Toronto	181		ref			ref
Turku	100	1.69	1.18–2.44	0.005	2.19	1.44–3.34	<0.001
Adj.chemotherapy No	219		ref						ref
Yes	62	0.88	0.57–1.36	0.57				0.60	0.37–0.99	0.044
Removed nodes
0	61		ref						ref
1–9	86	1.09	0.67–1.76	0.73				1.23	0.74–2.06	0.43
≤	134	0.78	0.49–1.24	0.29				0.78	0.47–1.29	0.33

In multivariate model #1 in addtion to clinicopathological variables (gender, age, grade, pT-category, and nodal status) study center is added to the model; In model #2 Adjuvant chemotherapy and node dissesction groups, but not center are included.